Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study

BACKGROUND: The efficacy of esketamine nasal spray (NS) as a rapid-acting agent for treatment resistant depression (TRD) was demonstrated in comparisons with placebo, when both were given in addition to a newly initiated selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira-Maia, Albino J., Rive, Benoit, Morrens, Joachim, Godinov, Yordan, Cabrieto, Jedelyn, Perualila, Nolen, Mulhern-Haughey, Siobhán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669145/
https://www.ncbi.nlm.nih.gov/pubmed/38025416
http://dx.doi.org/10.3389/fpsyt.2023.1250987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669145/
https://www.ncbi.nlm.nih.gov/pubmed/38025416
http://dx.doi.org/10.3389/fpsyt.2023.1250987

Ejemplares similares